Board Description
Claritas Pharmaceuticals is developing R-107, a nitric oxide-releasing molecule designed to treat vaccine-resistant COVID-19 infection.
Board Type
Claritas Pharmaceuticals is developing R-107, a nitric oxide-releasing molecule designed to treat vaccine-resistant COVID-19 infection.